Pre-made Simtuzumab benchmark antibody ( Whole mAb, anti-LOXL2 therapeutic antibody, Anti-LOR/LOR2/WS9-14 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-522

Pre-Made Simtuzumab biosimilar, Whole mAb, Anti-LOXL2 Antibody: Anti-LOR/LOR2/WS9-14 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-522-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Simtuzumab biosimilar, Whole mAb, Anti-LOXL2 Antibody: Anti-LOR/LOR2/WS9-14 therapeutic antibody
INN Name Simtuzumab
TargetLOXL2
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesArresto Biosciences;Gilead Sciences
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedColorectal cancer;Hepatic fibrosis;Idiopathic pulmonary fibrosis;Liver cirrhosis;Myelofibrosis;Non-alcoholic steatohepatitis;Pancreatic cancer;Primary sclerosing cholangitis
Development Techna